Sage Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to the development of novel therapies for central nervous system (CNS) disorders. Since its founding in 2010, the company has focused on harnessing the potential of neuroactive steroids to address conditions with significant unmet needs. Sage’s research platform centers on modulation of GABAergic and glutamatergic systems, with the goal of delivering rapid-acting, orally available treatments for mood, cognitive and seizure disorders.
The company’s first approved product, brexanolone (marketed as ZULRESSO®), received regulatory approval in multiple jurisdictions for the treatment of postpartum depression, marking the first drug approved specifically for this condition. Sage has since advanced zuranolone (SAGE-217), an investigational oral neuroactive steroid for major depressive disorder and postpartum depression, through late-stage clinical trials. In addition to its lead programs, Sage is progressing SAGE-324, an investigational compound for the treatment of focal and generalized tonic-clonic seizures, and SAGE-718, aimed at enhancing cognitive function in neurological diseases such as Alzheimer’s and Huntington’s.
Beyond its proprietary pipeline, Sage Therapeutics has established strategic collaborations to augment its global reach and accelerate development. The company conducts clinical trials across North America, Europe and Asia, leveraging partnerships with leading academic institutions and biopharmaceutical organizations. Sage has also entered licensing arrangements in select territories to support commercialization and regulatory activities, underscoring its commitment to bringing innovative CNS therapies to patients worldwide.
Under the leadership of President and Chief Executive Officer Jeff Jonas and Chief Financial Officer Mary Lynne Hedley, the company continues to build a multidisciplinary team of neuroscientists, clinical researchers and regulatory experts. Sage maintains a robust discovery engine alongside its clinical operations, investing in both small molecule and peptide-based approaches. Through this integrated model, Sage Therapeutics seeks to transform the treatment landscape for neurological and psychiatric disorders by advancing first-in-class and best-in-class therapies.
AI Generated. May Contain Errors.
Free SAGE Stock Alerts